Australia's Lumos Diagnostics rises on extension of Henry Schein agreement

Lumos Diagnostics Holdings

09/07/2024 03:57

** Shares of Lumos Diagnostics  LDX.AX  rise as much as 10%
to A$0.044, hitting their highest level since June 4
    ** Medical equipment supplier extends agreement with Henry
Schein's  HSIC.O  medical business in Europe for distribution of
FebriDx point-of-care test
    ** Co says FebriDx's rapid test helps differentiate a viral
from bacterial acute respiratory infection
    ** Under extended agreement, distribution of FebriDx
point-of-care test to expand to Belgium
    ** Stock has fallen 45.2% this year, as of last close

 (Reporting by Shivangi Lahiri in Bengaluru)
 ((shivangi.lahiri@thomsonreuters.com))